Repros Therapeutics Inc. (RPRX) Stock Price Down 4.2%
Shares of Repros Therapeutics Inc. (NASDAQ:RPRX) fell 4.2% during mid-day trading on Tuesday . The company traded as low as $1.70 and last traded at $2.06, with a volume of 715,816 shares trading hands. The stock had previously closed at $2.15.
Separately, Zacks Investment Research downgraded shares of Repros Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 13th. One investment analyst has rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. Repros Therapeutics currently has a consensus rating of “Hold” and an average price target of $21.50.
The company’s market cap is $50.82 million. The stock’s 50 day moving average price is $1.79 and its 200 day moving average price is $1.57.
Repros Therapeutics (NASDAQ:RPRX) last announced its quarterly earnings data on Tuesday, August 9th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.02. On average, analysts forecast that Repros Therapeutics Inc. will post ($0.75) earnings per share for the current year.
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include Androxal and Proellex. The Company’s primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.